Statistics from Altmetric.com
Biogen and AbbVie have announced the voluntary worldwide withdrawal of marketing authorisations for daclizumab (Zinbryta) for the treatment of relapsing multiple sclerosis (MS) as a result of the “complex and evolving benefit/risk profile” of the drug.1 Following seven reported cases of inflammatory brain disorders (encephalitis and meningoencephalitis) associated with daclizumab, the European Medicines Agency (EMA) has undertaken an urgent review of the safety of the drug.2
Clinicians will be contacted directly with further information about the withdrawal of …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.